Correction: Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer

Progression-free survival and overall survival by KRAS status (KRAS efficacy sets, central assessment). The proportion of patients with progression-free survival (top) and overall survival (bottom) over time (wk) are shown for patients in the Low/Negative EGFR study (left) and the High EGFR study (right). Vertical bars, censored observation.